In 2019, osimertinib, a third-generation TKI, was indicated by the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC as the first line drug against NSCLC with TKI-sensitive EGFR and T790M mutations (10). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.